What Is The Pneumonia Vaccine Called 4 Names To Know?

If you have ever gone looking for the “pneumonia shot,” you have probably run into a confusing wall of names. The word “pneumonia” is not actually part of any vaccine’s name. Instead, the vaccines are named after the bacterium they target: Streptococcus pneumoniae, often shortened to pneumococcus. That is why you see terms like pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on pharmacy forms instead of the plain word “pneumonia.”

The four names you are most likely to encounter are PCV15, PCV20, PCV21, and PPSV23. Two of these are conjugate vaccines, two are polysaccharide-based, and the numbers refer to how many strains of the bacterium each one covers. Knowing the difference helps you understand what your doctor is offering and why the recommendation may have changed in recent years.

What Is The Pneumonia Vaccine Called?

There is no single vaccine called “the pneumonia vaccine.” There is a family of vaccines that protect against invasive disease caused by Streptococcus pneumoniae, a bacterium responsible for pneumonia, bloodstream infections, and meningitis.

The bacterium is surrounded by a sugar coating called a polysaccharide capsule. That capsule is what the immune system learns to recognize. Different strains wear different capsules, and there are more than 90 known capsular types. Each vaccine is built to cover a specific set of them, which is exactly what the number after the letters tells you.

The two big categories are conjugate vaccines (PCV) and polysaccharide vaccines (PPSV). Conjugate vaccines link the bacterial sugar to a carrier protein. That protein tag makes the immune system respond more strongly and, importantly, helps create immune memory. Polysaccharide vaccines do not have that protein tag, so the response is weaker and shorter-lived.

What Is The Pneumonia Vaccine Called 4 Names To Know?

The four names in current use are PCV15, PCV20, PCV21, and PPSV23. Each covers a different breadth of strains, and each is used in different situations.

PCV15 is a conjugate vaccine covering 15 strains. PCV20 is a conjugate vaccine covering 20 strains. PCV21 is a conjugate vaccine covering 21 strains, though the specific strains it targets differ somewhat from PCV20. PPSV23 is a polysaccharide vaccine covering 23 strains.

Here is the counterintuitive part. PPSV23 covers the most strains on paper, but it does not produce the strongest or longest-lasting immune response. The conjugate vaccines cover fewer strains but generate a better immune memory. That is why conjugate vaccines are now the preferred first step for most adults who need protection, and PPSV23 is used in specific follow-up situations rather than as the primary choice.

What Is The Difference Between PCV15, PCV20, and PCV21?

All three are conjugate vaccines. The main differences are the number of strains covered and the specific strains chosen.

PCV15 was designed as an upgrade to earlier conjugate vaccines. PCV20 covers additional strains, including some that have become more common causes of disease in adults. PCV21 takes a different approach, targeting a set of strains selected to match what is actually circulating in adult populations, and it excludes some strains that rarely cause adult disease.

The practical effect is that a doctor choosing between them is weighing coverage against availability and local guidance. In many settings, PCV20 or PCV21 is now the preferred single-dose option for adults who have never received a pneumococcal vaccine, because one shot provides broad coverage without needing a follow-up dose of PPSV23.

No head-to-head trials have shown one of these three conjugate vaccines to be clearly superior at preventing disease in adults. The choice often comes down to what is available and what the current advisory guidance recommends.

What Is PPSV23 and How Is It Different?

PPSV23 is the polysaccharide vaccine, sometimes called Pneumovax 23. It has been in use since the 1980s and covers 23 strains of Streptococcus pneumoniae.

Because it is a polysaccharide vaccine without a carrier protein, it does not create the same durable immune memory that conjugate vaccines do. The protection it provides tends to fade faster. It also does not reliably produce a strong response in children under two years old, which is one reason conjugate vaccines were developed in the first place.

PPSV23 still has a role. It is often recommended as a follow-up dose for adults who received PCV15 first, and it may be used in certain high-risk groups. It is also sometimes given to people who have already received a conjugate vaccine in the past and need broader coverage.

The key point is that PPSV23 is no longer the go-to first vaccine for most adults. The conjugate vaccines have largely taken that role.

Who Should Get a Pneumococcal Vaccine?

Pneumococcal vaccination is recommended for adults 65 and older, and for adults 19 to 64 who have certain risk conditions. Those conditions include chronic heart disease, chronic lung disease (including asthma if treated with long-term steroids), diabetes, chronic liver disease, chronic kidney disease, smoking, and conditions that weaken the immune system such as HIV, cancer treatment, or organ transplant.

Children are also vaccinated. The routine childhood schedule uses a conjugate vaccine starting in infancy, typically at 2, 4, 6, and 12 to 15 months, though the exact schedule depends on which product is used. This has dramatically reduced invasive pneumococcal disease in children since it was introduced.

Adults who are unsure whether they need a pneumococcal vaccine should ask their doctor. The recommendation depends on age, health conditions, and what vaccines you have already received.

Why Do the Recommendations Keep Changing?

Pneumococcal vaccine recommendations have shifted repeatedly over the past decade. That is not because the earlier guidance was wrong. It is because the vaccines themselves improved, and because the strains causing disease changed over time.

When conjugate vaccines were first introduced for children, they reduced disease caused by the strains they covered. But other strains then became more common, a phenomenon called serotype replacement. Vaccine makers responded by adding more strains to the conjugate vaccines. As those broader vaccines became available, the guidance shifted toward using them as the primary option.

This is why an adult who received a pneumococcal vaccine years ago may now be told they need a different one. The goal is to match the vaccine to the strains currently causing disease and to the person’s current risk profile.

What About Side Effects and Safety?

The most common side effects are local reactions at the injection site: soreness, redness, and swelling. Some people experience fatigue, headache, muscle aches, or fever, usually mild and lasting a day or two.

Serious adverse events are rare. Anaphylaxis, a severe allergic reaction, is estimated to occur in fewer than one in a million doses, though exact figures vary by vaccine and population studied.

People with a history of severe allergic reaction to a vaccine component should not receive that vaccine. Anyone with a moderate or severe acute illness should generally wait until they recover before getting vaccinated. This is standard guidance for most vaccines, not specific to pneumococcal vaccines.

As with any medical decision, the balance of benefit and risk depends on individual circumstances. For most people at risk of pneumococcal disease, the benefits of vaccination are considered to outweigh the risks.